Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.- 66. (Cancelled).

67. (Currently amended) A composition of matter having the following formula:

IEM-PBM-[L]-[MS-MM]$_p$,

wherein p is 1;

wherein L comprises a physiologically compatible linker moiety which links the PBM and [MS-MM] moieties;

wherein said IEM comprises a complex between:

(1) a chelating agent selected from the group consisting of DTPA, DOTA, DTPA-BMA, and HP-DO3A, and

(2) one or more paramagnetic metal ions (M) with atomic numbers 21-29, 42, 44, or 57-83;

wherein said –PBM moiety is selected from the group consisting of:




; ; ;



;

;

; and

, wherein ~~at least~~ one aryl ring <u>of said –PBM</u> ~~of each member of the group~~ is substituted with said -<u>[L]-</u>[MS-MM]$_p$ moiety;

wherein R can be a linear or branched ~~alkyl~~ <u>aliphatic</u> group ~~having from 1 to 5 carbons~~, an aryl group, or a cycloalkyl group;

wherein the wavy line signifies the attachment site for the IEM;

wherein said -PBM moiety is conjugated to said IEM via a covalent bond to a methylene carbon of said chelating agent of said IEM;

wherein said MS moiety ~~comprises~~ <u>is</u> an amide bond;

wherein said MM moiety is a peptide ~~comprising~~ consisting of two ~~or more~~ or three ~~positively charged~~ amino acids;

and pharmaceutically acceptable salts thereof.

68. (Currently amended) The composition of claim 67, wherein said MM moiety is a peptide ~~comprising~~ consisting of two ~~or more~~ Arg, Lys, or tm-Lys amino acids, or mixtures thereof.

69. – 70. (Cancelled).

71. (Currently amended) The composition of claim ~~68~~ 67, wherein said MM moiety is –Arg-tmLys-tmLys.

72. (Currently amended) The composition of claim ~~68~~ 67, wherein said MM moiety is Ile-Arg-Lys.

73. (Currently amended) The composition of claim ~~68~~ 67, wherein said chelating agent is selected from the group consisting of:







and



wherein the wavy line signifies the attachment site for the -PBM-L-MS-MM moiety.

74. (Currently amended) The composition of claim ~~68~~ 67, wherein said chelating agent is



wherein the wavy line signifies the attachment site for the -PBM-L-MS-MM moiety.

75. (Previously presented) The composition of claim 67, wherein said paramagnetic metal ion is selected from the group consisting of:

(a) Gd (III),

(b) Mn (II),

(c) Fe (III),

(d) Cu (II),

(e) Cr (III), and

(f) Eu (III).

76. (Previously presented) The composition of claim 75, wherein said paramagnetic metal ion is Gd(III).

77. (Previously presented) The composition of claim 67, wherein the pharmaceutically acceptable salt is an N-methyl-D-glucamine, calcium, or sodium salt.

78. (Previously presented) The composition of claim 77, wherein the pharmaceutically acceptable salt is a sodium salt.

79. – 80. (Cancelled).

81. (Currently amended) A composition of matter having the following structure ~~formula~~:

~~IEM-PBM-(MS-MM),~~




wherein said IEM comprises a complex between:

(1) a chelating agent selected from the group consisting of DTPA, DOTA, DTPA-BMA, and HP-DO3A, and

(2) one or more paramagnetic metal ions (M) with atomic numbers 21-29, 42, 44, or 57-83;

~~said composition having the structure:~~

wherein ~~at least~~ one aryl ring of said structure is substituted with ~~said~~ a L-$[MS\text{-}MM]_p$ moiety, wherein p is one;

wherein X is $CH_2$, O, or NH;

wherein L comprises a physiologically compatible linker moiety which links said one substituted aryl ring with said -$[MS\text{-}MM]_p$ moiety;

wherein said MS moiety ~~comprises~~ is an amide bond;

wherein said MM moiety is a peptide ~~comprising~~ consisting of two ~~or more~~ or three ~~positively charged~~ amino acids;

and pharmaceutically acceptable salts thereof.

82. (Currently amended) The composition of claim 81, wherein said MM moiety is a peptide ~~comprising~~ consisting of two ~~or more~~ Arg, Lys, or tm-Lys amino acids, or mixtures thereof.

83. – 84. (Cancelled).

85. (Currently amended) The composition of claim ~~82~~ 81, wherein said MM moiety is -Arg-tmLys-tmLys.

86. (Currently amended) The composition of claim ~~82~~ 81, wherein said MM moiety is Ile-Arg-Lys.

87. (Currently amended) The composition of claim 81, wherein said chelating agent is selected from the group consisting of:







and



~~wherein the wavy line signifies the attachment site for the PBM-MS-MM moiety~~.

88. (Currently amended) The composition of claim 87, wherein said chelating agent is




~~wherein the wavy line signifies the attachment site for the PBM-MS-MM moiety~~.

89. (Previously presented) The composition of claim 81, wherein said paramagnetic metal ion is selected from the group consisting of:

(a) Gd (III),

(b) Mn (II),

(c) Fe (III),

(d) Cu (II),

(e) Cr (III), and

(f) Eu (III).

90. (Previously presented) The composition of claim 89, wherein said paramagnetic metal ion is Gd(III).

91. (Previously presented) The composition of claim 81, wherein the pharmaceutically acceptable salt is an N-methyl-D-glucamine, calcium, or sodium salt.

92. (Previously presented) The composition of claim 91, wherein said pharmaceutically acceptable salt is a sodium salt.

93. – 94. (Cancelled).

95. (Currently amended) A method for magnetic resonance imaging, said method comprising:

a) administering to a mammal the composition of matter of claim 67 or 81,

b) allowing the composition of matter to be bioactivated;

c) allowing said bioactivated composition of matter to bind to a protein on the extracellular surface of a tissue or in extracellular fluid surrounding a tissue, said tissue containing a bioactivity to be detected; and

d) subjecting said mammal to magnetic resonance imaging.

96. (Currently amended) ~~The~~ A compound ~~according to claim 81~~ having the structure of Prodrug Compound 2:




---

or Prodrug Compound 10:




---

~~as set forth in the specification~~.

97. (New) The composition of claim 67 or 81, wherein said L moiety is a peptoid linkage.

98. (New) The composition of claim 67 or 81, wherein said L moiety has the following structure: